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Background: Iliac artery atherosclerotic disease may cause intermittent claudication and critical limb ischemia. It can
lead to serious complications such as infection, amputation and even death. Revascularization relieves symptoms and
prevents these complications. Historically, open surgical repair, in the form of endarterectomy or bypass, was used.
Over the last decade, endovascular repair has become the first choice of treatment for iliac arterial occlusive disease. No
definitive consensus has emerged about the best endovascular strategy and which type of stent, if any, to use.
However, in more advanced disease, that is, long or multiple stenoses or occlusions, literature is most supportive of
primary stenting with a balloon-expandable stent in the common iliac artery (Jongkind V et al., J Vasc Surg 52:1376-
1383,2010). Recently, a PTFE-covered balloon-expandable stent (Advanta V12, Atrium Medical Inc., Hudson, NH, USA)
has been introduced for the iliac artery. Covering stents with PTFE has been shown to lead to less neo-intimal
hyperplasia and this might lower restenosis rates (Dolmatch B et al. J Vasc Interv Radiol 18:527-534,2007, Marin ML et al.
J Vasc Interv Radiol 7:651-656,1996, Virmani R et al. J Vasc Interv Radiol 10:445-456,1999). However, only one RCT, of
mediocre quality has been published on this stent in the common iliac artery (Mwipatayi BP et al. J Vasc Surg 54:1561-
1570,2011, Bekken JA et al. J Vasc Surg 55:1545-1546,2012). Our hypothesis is that covered balloon-expandable stents
lead to better results when compared to uncovered balloon-expandable stents.
Methods/Design: This is a prospective, randomized, controlled, double-blind, multi-center trial. The study population
consists of human volunteers aged over 18 years, with symptomatic advanced atherosclerotic disease of the common
iliac artery, defined as stenoses longer than 3 cm and occlusions. A total of 174 patients will be included.
The control group will undergo endovascular dilatation or revascularization of the common iliac artery, followed by
placement of one or more uncovered balloon-expandable stents. The study group will undergo the same treatment,
however one or more PTFE-covered balloon-expandable stents will be placed. When necessary, the aorta, external iliac
artery, common femoral artery, superficial femoral artery and deep femoral artery will be treated, using the standard
treatment.
The primary endpoint is absence of binary restenosis rate. Secondary endpoints are reocclusion rate, target-lesion
revascularization rate, clinical success, procedural success, hemodynamic success, major amputation rate, complication
rate and mortality rate. Main study parameters are age, gender, relevant co-morbidity, and several patient, disease and
procedure-related parameters.
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Trial registration: Dutch Trial Register, NTR3381.
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Critical Limb Ischemia, Endovascular, Stenting, Covered stentBackground
Peripheral Arterial Occlusive Disease (PAOD) is a dis-
ease defined as reduced arterial blood flow to the lower
extremities due to atherosclerotic arterial lesions and is
diagnosed by an ankle-brachial index less than 0.9. It
may lead to intermittent claudication (IC) or, with pro-
gression of the disease, critical limb ischemia (CLI). Only
one out of every four to five patients with PAOD will be
symptomatic [1]. The most common clinical manifest-
ation of PAOD is intermittent claudication involving the
pelvis, upper thigh and lower limb. It is defined as ische-
mic pain occurring during exercise, which is quickly
relieved with rest (Fontaine II, Rutherford 1 to 3). CLI is
a more severe presentation of PAOD, defined as ische-
mic rest pain (Fontaine III, Rutherford 4) or ischemic
skin lesions: either ulcers or gangrene (Fontaine IV,
Rutherford 5 and 6, respectively) [1]. See Table 1 for a
description of the Rutherford classification. Patients pre-
senting with CLI usually have multisegmental disease
with involvement of the infra-inguinal arteries [2]. Ten
to twenty percent of patients with IC will progress to
CLI in the course of their disease [3-6]. The most im-
portant risk factors for progression to the advanced form
of PAOD are age, tobacco use and diabetes mellitus [6].
Epidemiology
Newman et al. [7] described the prevalence of PAOD
(asymptomatic and symptomatic) in the general popula-
tion. They found a prevalence of 13.4% in those over 65
years of age, rising to 21.6% in those over 75 years ofTable 1 Overview of the Rutherford-classification for PAOD
Grade Category Clinical description
0 0 Asymptomatic - no hemodynamically significant
occlusive disease
1 Mild claudication
I 2 Moderate claudication
3 Severe claudication
II 4 Ischemic rest pain
III 5 Minor tissue loss - nonhealing ulcer, focal gangrene with
diffuse pedal ischemia
6 Major tissue loss - extending above TM level, functional
foot no longer salvageable
AP = Ankle pressure, PAOD = Peripheral Arterial Occlusive Disease, PVR = pulse volage. The German getABI study [8] showed a prevalence
of 19.8% in men over 65, and 16.8% in women over 65.
The exact overall incidence of PAOD is not known, but
the Framingham Study showed an incidence of IC of 26/
10,000 in men and 12/10,000 in women [9]. Anatomic-
ally, approximately 30% of the arterial lesions in PAOD
are located in the iliac arteries [6].Endovascular treatment
In 1964, one year before the technique was used for cor-
onary arteries, the endovascular approach for treating
aorto-iliac lesions was introduced by Charles Dotter
[10]. In 1974, a catheter-mounted inflatable balloon that
could fit over a guidewire was developed by Andreas
Grüntzig, significantly improving the technique [11]. Fi-
nally, in 1985, the first intraluminal stent was developed
by Julio Palmaz, further improving the results of endo-
vascular treatment [12].
Despite the introduction of endovascular treatment in
1964, open surgical treatment has long been the treat-
ment of choice. Open surgical repair provides good
long-term patency (IC: 85 to 92%, CLI: 78 to 83%) [13].
The perioperative morbidity and mortality, however, is
substantial [13-17]. Due to ongoing improvements in
materials and techniques over the past decades, endo-
vascular techniques for aorto-iliac obstuctions have
more and more replaced open surgical repair. These
minimally invasive techniques show reduced morbidity
and mortality when compared to open surgery [18-21].Objective criteria
Normal treadmill test and ABI ≥0.9
Completes treadmill test. AP after exercise >50 mmHg, but at least 20
mmHg lower than resting value
Between categories 1 and 3
Cannot complete treadmill test and AP after exercise <50 mmHg
Resting AP <40 mmHg, flat or barely pulsatile ankle or metatarsal PVR,
TP <30 mmHg
Resting AP <60 mmHg, ankle or metatarsal PVR flat or barely pulsatile,
TP <40 mmHg
Same as category 5
ume recording, TP = Toe pressure.
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Aorto-iliac Occlusive Disease (AIOD) is classified by the
Trans Atlantic Inter-Society Consensus on the Manage-
ment of Peripheral Arterial Disease (TASC II). This clas-
sification divides AIOD into four types (see Figure 1),
based on the amenability to endovascular repair. The
current TASC guidelines were published in 2007 [1] andFigure 1 The TASC II classification of aortoiliac lesions.recommend an endovascular approach in type A and B
lesions, and an open surgical approach for type C and D
lesions. Endovascular repair is only recommended in
patients with type C lesions, who have a low healing po-
tential following surgical revascularization. However, a
recent meta-analysis was published by Jongkind et al.
reporting on endovascular treatment for extensive AIOD
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cohort studies, containing 1,711 patients were included.
Although 4- and 5-year primary patency rates for endo-
vascular repair were lower compared to open surgical
treatment (60 to 86%), the secondary patency rates were
comparable (80 to 98%), with most reinterventions per-
formed endovascularly. Two studies retrospectively com-
pared open and endovascular therapy. Significantly
lower perioperative morbidity and shorter hospital stay
was reported in the endovascular group. Three- and
four-year primary patency rates were also significantly
lower for the endovascular group (69% vs 93%, P = 0.013
and 74% vs 93%, P = 0.002), however secondary patency
was comparable with surgical repair (89% vs 100%, P
>0.05 and 95% vs 97%, P = 0.3) [22,23].
PTA or PTA with stenting for iliac obstructions
When treating AIOD endovascularly, there has been
some debate on whether to stent all lesions (‘direct’ or
‘primary’ stenting) or to perform balloon dilatation and
only place a stent on indication, such as dissection or re-
sidual stenosis (‘selective’ stenting). A meta-analysis per-
formed by Bosch et al. [24] in 1997 compared these two
methods. A total of 1,300 selective stent patients (6 stud-
ies) and 816 direct stent patients (8 studies), were com-
pared. This study showed higher technical success and
patency rates after direct stenting. However, a rando-
mized controlled trial conducted by the same group,
published in 1998, showed, after 5 to 8 years of follow-
up, no significant difference in iliac patency and ABI. A
small, but significant, difference in symptomatic success
was found, in favor of selective stenting [25,26]. These
results are equivocal, due to a low technical success rate
(approximately 80%) and the exclusion of advanced dis-
ease. Since then, an overwhelming amount of studies
have shown favorable results of direct stenting, espe-
cially in TASC C and D lesions [2,20,22,23,27-40]. In the
aforementioned review by Jongkind et al., 15 out of 19
included studies employed direct stenting rather than se-
lective stenting. Therefore, evidence for direct stenting
in simple disease is lacking compared to more advanced
disease, where literature supports the employment of
this strategy.
Distal outflow after endovascular repair
Several studies have shown that decreased outflow leads
to lower patency rates and that, when treating the iliac
artery endovascularly, sufficient outflow from the com-
mon femoral artery is mandatory [37,41].
Balloon-expandable or self-expanding stents for iliac
obstructions
Balloon-expandable stents are usually made of stainless
steel, while self-expanding stents are usually made ofNitinol, an alloy of nickel and titanium. Nitinol is a ‘ther-
mal memory’ alloy which can be heat-treated to assume
a predetermined shape above a set temperature, which
in this case is 30C. Balloon-expandable stents are char-
acterized by much greater radial strength, compared to
self-expanding stents. Self-expanding stents, on the
other hand, have greater elasticity, allowing them to re-
gain their shape after the compressing force reduces.
Another advantage of self-expanding stents is their
higher trackability, meaning they are easier to maneuver
through tortuous vessels or past the aortic bifurcation in
the contralateral approach. Balloon-expandable stents
generally have higher radiopacity, which facilitates accur-
ate placement [42]. Due to its greater flexibility and elas-
ticity, self-expanding stents are advised in tortuous
vessels, over joints and in mechanically exposed vessels
(subclavian and popliteal arteries). On the other hand, in
rigid and straight lesions balloon-expandable stents are
generally considered more appropriate [43,44].
Bare or covered stents for iliac obstructions
One of the main causes for late failure after stent place-
ment is in-stent stenosis, predominantly caused by neo-
intimal hyperplasia [45]. The wall injury inherent to any
vascular intervention leads to the exposure of underlying
atheromatous tissue and the elution of macromolecules,
among them pro-inflammatory mediators. These attract
macrophages that transmigrate into the vascular wall to
release further cytokines, metalloproteinase, and growth
factors that play a role in initiating the restenotic
process. Therefore, endoluminal sealing of the vessel
with a membrane covered stent may potentially inhibit
restenosis formation [46]. The stent-covering materials
are the same that have been used for bypass grafts: poly-
ethylene terephthalate (PET, brand name Dacron) and
polytetrafluoroethylene (PTFE, brand name Teflon). Of
these two frequently used fabrics, PET has the downside
of being more thrombogenic than PTFE [47]. In con-
cordance with this, studies investigating Dacron-covered
stent grafts in iliac and femoral arteries have shown dis-
appointing results [48-50]. Therefore, current research
has been focused on PTFE-covered stents. PTFE for vas-
cular prosthetic applications is known as expanded poly-
tetrafluoroethylene (ePTFE). Expansion is part of the
manufacturing process to modify the solid material into
a porous lattice. When PTFE is used to cover a balloon-
expandable metal stent, the material dilates simultan-
eously with the stent, with a resulting decrease in the
material wall thickness [45].
Several studies have been published describing the
results of PTFE-covered stents in PAOD of the iliac ar-
tery. These are shown in Table 2.
As shown in Table 2, primary patency rates of covered
stents are excellent. However, most studies are either
Table 2 Results of studies reporting on the results of PTFE-covered stents for PAOD in the iliac artery
Author, year Type of study Number Type of stent Freedom of binary restenosis
Covered Uncovered
Sabri, 2010 [54] Retrospective, comparative 26 covered Balloon-expandable 1 year: 92% 1 year:78%,
28 uncovered 2 year:92%, 2 year: 62%
Lammer, 2000 [61] Prospective 61 Self-expanding 6 month: 98%,
1 year: 91%
Wiesinger, 2005 [62] Prospective 60 Self-expanding 6 month: 94%,
1 year: 91%
Bosiers, 2007 [63] Prospective 91 Balloon-expandable 1 year: 91%
Chang, 2008 [53] Retrospective, comparative 71 covered Mostly self-expanding 5 year: 87% 5 year: 53%
122 uncovered
Mwipatayi, 2011 Randomized controlled trial 83 covered Both 18 month: 92% 18 month: 75%
84 uncovered
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randomized controlled trial has been performed, which
is the COBEST-trial (Covered versus Balloon Expandable
Stent Trial). This trial compares the Advanta V12
balloon-expandable PTFE-covered stent versus uncov-
ered stents. In this trial, various types of uncovered
stents are used, including self-expanding. Since balloon-
expandable and self-expanding stents have very different
characteristics, this is likely to influence the results.
Some of the other drawbacks of this study include usage
of the TASC-classification for sub-group analysis, and
making no distinction between the CIA and the EIA.
The TASC-classification is a very general and
heterogenous classification, making it useful for day to
day practice, but not so much for research purposes.
Categorizing subgroups based on specific lesion charac-
teristics (such as occlusion vs stenosis, and length of the
lesion), allows for much more accurate analysis. Further-
more, the external and common iliac have very different
anatomical characteristics. Where the CIA is a straight
and immobile vessel, being fixed to the sacral promon-
tory, the EIA has a much more tortuous course, along
with stretching during extension of the hip [51]. To our
knowledge, no comparative studies have been published
on this topic, but biomechanical studies do confirm our
opinion [42]. Furthermore, a retrospective study showed
a decreased patency rate after stent placement in the
EIA compared to a similar treatment in the CIA [52]. In
this trial, we will avoid these flaws, and perform a more
methodologically and scientifically solid study, by focus-
ing on just the CIA, and using lesion characteristics, ra-
ther than the TASC-classification, to classify lesions.
Conclusion and rationale of this study
A primary endovascular approach should be attempted
in all patients with PAOD and iliac lesions. When per-
forming endovascular repair, there are many differentstrategies and types of stents to be used, as described
above. There is no general consensus on which strategy
and type of stent is best for which artery. However, for
more advanced disease of the common iliac artery, lit-
erature is most supportive of direct stenting with a
balloon-expandable stent. A recent innovation in this
area is the PTFE-covered stent, which might further im-
prove the primary patency of iliac stenting. However,
only one RCT, of mediocre quality and several small co-
hort studies and retrospective comparative studies on
this subject are available. Therefore, the purpose of this
study is to compare PTFE covered balloon-expandable
stents with non-covered balloon-expandable stents in
patients with advanced occlusive disease in the common
iliac artery, defined as stenoses longer than 3 cm and




 To assess the absence of binary restenosis rate of
advanced atherosclerotic lesions of the common iliac
artery with a balloon-expandable PTFE-covered stent
(Advanta V12, Atrium Medical Inc., Hudson, NH,
USA), when compared to selected balloon-expandable
uncovered stents, in a 2-year follow-up period.
Secondary objectives
 To assess the reocclusion rate and target-lesion
revascularization rate after endovascular treatment of
advanced atherosclerotic lesions of the common iliac
artery with a balloon- expandable PTFE-covered stent
(Advanta V12, Atrium Medical Inc., Hudson, NH,
USA), when compared to selected balloon-expandable
uncovered stents, in a 2-year follow-up period.
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treatment of advanced atherosclerotic lesions of the
common iliac artery with a balloon-expandable
PTFE-covered stent (Advanta V12, Atrium Medical
Inc., Hudson, NH, USA), when compared to
selected balloon-expandable uncovered stents, in a
2-year follow-up period.
 To assess clinical outcome after endovascular
treatment of advanced atherosclerotic lesions of the
common iliac artery with a balloon-expandable
PTFE-covered stent (Advanta V12, Atrium Medical
Inc., Hudson, NH, USA), when compared to
selected balloon- expandable uncovered stents, in a
2-year follow-up period.
 To assess hemodynamic outcome after endovascular
treatment of advanced atherosclerotic lesions of the
common iliac artery with a balloon expandable
PTFE-covered stent (Advanta V12, Atrium Medical
Inc., Hudson, NH, USA), when compared to
selected balloon- expandable uncovered stents, in a
2-year follow-up period.
 To assess the complication rate, mortality rate and
amputation rate after endovascular treatment of
advanced atherosclerotic lesions of the common
iliac artery with a balloon-expandable PTFE-covered
stent (Advanta V12, Atrium Medical Inc., Hudson,
NH, USA), when compared to selected balloon-
expandable uncovered stents, in a 2-year follow-up
period.
Study Design
A prospective, randomized, controlled, double-blind,
multi-center trial with a follow-up period of 2 years.
Centers currently participating are:
 Maasstad Hospital, Rotterdam, The Netherlands
 Sint Antonius Hospital, Nieuwegein, The
Netherlands
More centers may be added during the course of the
trial.
Study population
Patients with symptomatic, advanced atherosclerotic
lesions of the common iliac artery presenting at one of
the participating hospitals.
Inclusion criteria
 Age over 18;
 Symptomatic, atherosclerotic lesion of the
common iliac artery, either a hemodynamically
significant stenosis with a length of more than 3
cm, or an occlusion. This will be measured onthe pre-dilation DSA-images, where a diameter
reduction of >50% is considered significant. A
hemodynamically significant stenosis is
confirmed with an intra-arterial translesional
systolic blood pressure gradient measurement,
where >10 mmHg pressure gradient is
considered significant. Serial lesions less than 2
cm apart will be regarded as one long stenosis;
 Signed informed consent form.
Exclusion criteria
 Stenosis with a length of less than 3 cm;
 Presence of a metastatic malignancy, or other
disease that limits life expectancy to less than 2
years;
 Previous endovascular or surgical treatment of the
common iliac artery on the affected side;
 Inability or unwillingness to comply with the follow-
up schedule;
 Mental disability or language barrier that hinders
the ability to understand and comply with the
informed consent;
 Pregnancy or breast-feeding;
 Severe renal failure (e-GFR <30 mL/min/1.73 m2);
 Known allergy to iodinated contrast agents or to
PTFE;
 Contra-indication for anti-coagulation;
 Acute limb ischemia;
 Occlusion of the abdominal aorta;
 Aneurysm of the abdominal aorta that is not
amenable to endograft placement.
Sample size calculation
Based on the available literature [53,54], we expect a 2-
year absence of binary restenosis rate of 90% in the
PTFE-covered stent group, and a 2-year absence of bin-
ary restenosis rate of 72% in the uncovered stent group.
Based on the log rank test for equality of survival curves,
with an alpha error level of 0.05 and a beta error level of
0.2, 79 patients per group will be necessary. We antici-
pate a loss to follow-up of less than 10%, so we will in-
clude 87 patients per group, for a total of 174 patients.
This calculation was performed using nQuery Advisor
(Statistical Solutions Ltd., Farmer’s Cross, Ireland). The
combined participating centers perform over 200 endo-
vascular procedures for advanced iliac PAOD annually.
With an estimated participation rate of 75%, estimated
inclusion time is 2 years.
No sample size calculation was performed for the sub-
groups as there is no data available on freedom of binary
restenosis rates for these groups, and therefore no well-
founded calculation can be made.
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The aim of the treatment is to obtain a patent aorta,
common and external iliac artery and a patent common
femoral artery with outflow via at least the superficial or
deep femoral artery. Therefore, not only the common
iliac artery will be treated, but if indicated, the aorta, ex-
ternal iliac artery and the common femoral artery will be
treated additionally. This strategy corresponds with daily
practice.
The common iliac artery will be treated with PTA and
direct stent placement. Patients will be randomized to
either the Advanta V12 PTFE-covered stent (Atrium
Medical Inc., Hudson, NH, USA) or a balloon-
expandable uncovered stent (see ’Investigational prod-
uct’). If the aorta needs additional treatment, the phys-
ician is free to use the following techniques: PTA or
PTA and balloon-expandable stent placement. If the ex-
ternal iliac artery needs additional treatment, the phys-
ician is free to use the following techniques: remote
endarterectomy, PTA or PTA and self-expandable
uncovered stent placement. If the common femoral ar-
tery needs additional treatment, an endarterectomy is
indicated. Patients will be treated under local anesthesia
for totally endovascular procedures and under regional
or general anesthesia if an additional endarterectomy is
warranted.
Treatment of the common iliac artery
A 6F or 7F sheath (depending on the type and diameter
of the stent) is introduced into the ipsilateral common
femoral artery. If necessary an adjunctive contralateral
approach may be used at the discretion of the physician,
either to make angiographic images, or to facilitate pas-
sage of the diseased segment. All patients receive 5,000
units of unfractionated heparin. A diagnostic catheter is
introduced into the aorta over a 0.035-inch guidewire.
Digital Subtraction Angiography (DSA) is performed
and saved according to protocol. In stenoses, the pres-
sure gradient is measured using a 70cm straight catheter
(4F) without side holes, which is withdrawn through the
stenosis. A translesional systolic blood pressure gradient
of >10mmHg is considered significant. The pressure gra-
dient, as well as absolute pressures, are documented.
The length of the diseased segment is measured per-
operatively on the DSA-images, and based on the pres-
sure gradient and length measurement the final decision
is made whether or not to include and randomize the
subject. Any occlusion is included, as well as any sten-
osis longer than 3 cm. Serial lesions less than 2 cm apart
will be regarded as one long stenosis and will be
randomized.
Based on randomisation, an Advanta V12 stent or a
balloon-expandable uncovered stent is placed. A stenosis
should be fully covered by the stent, including 5mmproximal and distal to the stenosis, based on the inflated
length of the stent. In case of proximal lesions, in which
the stent would extend into the aorta, and in distal
lesions, in which the stent would cover the internal iliac
artery (IIA), this 5mm margin is not mandatory. In case
of a stenosis including the distal aorta or iliac bifur-
cation, ‘kissing stents’ will be placed, which will extend
into the aorta. In case of a stenosis extending into the
EIA, the lesion in the CIA will be treated with a balloon-
expandable stent. The stenotic segment extending into
the EIA will be treated with PTA alone, PTA and a self-
expanding stent or remote endarterectomy. We try to
avoid covering the IIA with a stent.
In case of recanalization of a total occlusion, at least
the recanalized segment and any adjoining stenoses
should be fully covered by the stent, including 5mm
proximal and distal to the stenosis. The diameter will be
measured on the DSA-images, based on the diameter of
a healthy segment on the ipsilateral side. In case there is
no healthy segment, or in case of occlusion, the contra-
lateral CIA will be used for measurement. In case of bi-
lateral occlusion, the pre-operative CT-angiography or
MR-angiography will be used to measure the CIA diam-
eter. After measurement of the common iliac artery
diameter all stents are a maximum of 0.5mm oversized.
The balloon is longer than the stent and extends out of
the stent. When inflating the balloon, the shape of the
balloon has some resemblance to a dog bone. If the bal-
loon is oversized more than 0.5mm, the expanding bal-
loon outside the stent is thought to damage the artery
wall, causing local activation and progression of the ath-
erosclerotic process at the edge of the stent.
After stent placement a completion DSA is performed
according to protocol and saved, and the pressure gradi-
ent is once again measured and documented, as
described previously. Less than 30% residual diameter
reduction of the treated lesion and a systolic pressure
gradient of less than 5 mmHg will be considered a tech-
nical success. The stent location will be documented by
describing the exact distance from the aortic bifurcation
and the iliac bifurcation. This will ease localization of
the stent on DUS during follow-up.
After removal of the sheath(s) a closure device may be
used.
Treatment of the aorta
An additional hemodynamically significant stenosis in
the aorta must be treated by either PTA or PTA and
balloon-expandable uncovered stent placement. For the
endovascular treatment of the aorta, as far as we know,
there is no evidence, which supports direct stenting.
Therefore, we consider PTA, with stenting only on indi-
cation, the standard treatment. The PTA balloon and
stent should be 1mm oversized.
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An additional hemodynamically significant stenosis
or occlusion in the external iliac artery must be trea-
ted by either remote endarterectomy, PTA or PTA
and self-expandable uncovered stent placement. We
believe that for the EIA self-expandable stents are
more appropriate, due to the tortuosity of the artery
and its movement during flexion of the hip. As for
the aorta, for the EIA there is also no evidence as
far as we know, which supports direct stenting. Of
course, since these two types of stents have a very
different biomechanical behaviour, evidence on the
use of balloon-expandable stents should not be
extrapolated to self-expanding stents. The PTA bal-
loon and stent should be 1mm oversized. After reca-
nalization of an occluded external iliac artery PTA
and additional self-expandable uncovered stent
placement is warranted.
Treatment of the common femoral artery
A hemodynamically significant stenosis or occlusion of
the common femoral artery must be treated by endarter-
ectomy. This procedure will be combined with treatment
of the common iliac artery and, if indicated, external
iliac artery. If there is no appropriate outflow from either
the superficial or deep femoral artery, the physician may
choose to obtain sufficient outflow by using remote end-
arterectomy, recanalisation with or without stent place-
ment, or bypass.
Medication
All patients receive Aspirin 100mg daily and Simvastatin
40mg daily, indefinitely, starting at least one day prior to
the procedure. During the intervention all patients re-
ceive 5,000 units of Heparin. After the intervention all
patients receive Clopidogrel 75mg daily for a period of 4
weeks.
Investigational product
Name and description of investigational product
The Advanta V12 stent (Atrium Medical Inc., Hudson,
NH, USA) is a balloon-expandable stainless steel stent
that is fully encapsulated in two layers of PTFE. The
PTFE has a porosity of 100 to 120 μm. The Advanta V12
covered stent is available in diameters of 5 to 10 mm.
Available stent lengths are 16, 22, 38, and 59 mm. All
V12 stents are 0.035-inch guidewire compatible and are
pre-mounted on a 7F non-compliant balloon catheter
with gold markers embedded at the ends of the balloon.
Available catheter lengths are 80 and 120 cm. It is the
only balloon-expandable PTFE-covered stent that is
registered for use in the iliac artery in Europe.Name and description of control group products
In the control group, several uncovered balloon-
expandable stents have been selected to choose from at
the physician’s discretion. These stents are currently
used in the participating centers.
Omnilink Elite stent (Abbott Laboratories, North
Chicago, IL, USA). The Omnilink Elite is a balloon-
expandable CoCr (cobalt chromium alloy) stent. It is
available in diameters of 4 to 10 mm. Available lengths
are 12, 16, 19, 29, 39 and 59 mm. All Omnilink Elite
stents are 0.035-inch guidewire compatible and are pre-
mounted on a 6F dual layer compliant balloon catheter.
Available catheter lengths are 80 and 135 cm. It is
registered for use in the iliac artery in Europe.
Dynamic stent (Biotronik, Berlin, Germany). The
Dynamic stent is a balloon-expandable stainless steel
stent, with the stent struts coated with an amorphous
silicon carbide coating. It is available in diameters of 5
to 10 mm. Available lengths are 15, 25, 38 and 56 mm.
All Dynamic stents are 0.035-inch guidewire
compatible and are pre-mounted on a 6 or 7F
compliant balloon catheter. Available catheter lengths
are 80 and 130 cm. It is registered for use in the iliac
artery in Europe.
Express LD Iliac stent (Boston Scientific, Natick, MA,
USA). The Express LD Iliac is a balloon-expandable
stainless steel stent. It is available in diameters of 6 to
10 mm. Available lengths are 20, 30, 40 and 60 mm. All
Express LD Iliac stents are 0.035-inch guidewire
compatible and are pre-mounted on a 6 or 7F
compliant balloon catheter. Available catheter lengths
are 75 and 135 cm. It is registered for use in the iliac
artery in Europe.
Palmaz Genesis stent (Cordis Corporation, Bridgewater,
NJ, USA). The Palmaz Genesis is a balloon-expandable
stainless steel stent. It is available in diameters of 4 to
10 mm. Available lengths are 12, 15, 18, 19, 24, 25, 29,
39 and 59 and 79 mm. In the participating centers, we
only use 24, 39, 59 and 79 in the common iliac artery.
All Palmaz Genesis Iliac stents are 0.035-inch
guidewire compatible and are pre-mounted on a 6 or
7F compliant balloon catheter. Available catheter
lengths are 80 and 135 cm. It is registered for use in
the iliac artery in Europe.
Scuba stent (INVATEC S.p.A, Roncadelle, Italy). The
Scuba stent is a balloon-expandable CoCr (cobalt
chromium alloy) stent. It is available in diameters of 5
to 10 mm. Available lengths are 18, 30, 37, 55 and 75
mm. All Scuba stents are 0.035-inch guidewire
compatible and are pre-mounted on a 5F compliant
balloon catheter. Available catheter lengths are 80 and
130 cm. It is registered for use in the iliac artery in
Europe.
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Definitions of endpoints and parameters are in con-
cordance with the proposed definitions by the DE-
FINE group, a multidisciplinary team from various
specialties involved in PAOD therapies, from Europe
and the USA, which has made a case for more stan-
dardized reporting in studies for endovascular treat-
ment of PAOD [55,56].
Primary endpoint
 Absence of binary restenosis rate. Defined as the
percentage of limbs with absence of
hemodynamically significant obstruction in the
target-lesion after endovascular treatment.
Secondary endpoints
 Reocclusion rate. Defined as complete occlusion of
the initially treated target-lesion.
 Target-lesion revascularization (TLR) rate. Defined
as the rate and frequency of the need for repeated
procedures (endovascular or open surgical) due to a
problem arising from the target-lesion (+1 cm
proximally and distally to include edge phenomena)
in surviving patients with preserved limb.
 Immediate outcome:
– Procedural success. Defined as the combination
of technical success, device success and absence
of procedural complications.
– Technical success. Defined as successful vascular
access and completion of the endovascular
procedure and immediate morphological success
with less than 30% residual diameter reduction of
the treated lesion on completion and a systolic
pressure gradient of less than 5 mmHg.
– Device success. Defined as exact deployment of
the device, according to the instructions for use,
using the assigned device only. Clinical outcome:
– Distribution of Rutherford stages during follow-
up as compared to baseline.
– Functional outcome:▪ In patients with IC: Improvement in
claudication onset time (COT) and absolute
claudicating time (ACT) on standardized
treadmill test.
– Improvement in disease-related health status,
functioning and quality of life. As defined by the
Walking Impairment Questionnaire (WIQ) and
RAND-36 questionnaire. Hemodynamic outcome:
– Mean and median ABI during follow-up as
compared to baseline. Morphological outcome:
– Acute diameter gain (change in minimal luminal
diameter from base-line to post-intervention.
 Target-extremity revascularization (TER) rate. Defined
as the rate and frequency of the need for repeated
procedures (endovascular or open surgical) due to a
problem arising remote from the target-lesion in
surviving patients with preserved limb.
 Mortality rate. Mortality rate associated with the
endovascular procedure (that is, mortality within 30
days post-procedure or mortality during a
hospitalization >30 days due to the procedure) will
be reported separately, as well as overall mortality.
 Complication rate. In contrast with AE’s and SAE’s,
which do not need to be related to the treatment,
only complications that are (likely) related to the
treatment will be reported. This is at the discretion
of the investigator.
– Complications will be scored as ‘major’ or minor’.
A major complication is a complication that:
▪ Leads to death;
▪ Results in a life-threatening illness or injury;
▪ Results in permanent impairment of a body
structure or bodily function;
▪ Requires inpatient hospitalization or
prolongation of existing hospitalization;
▪ Results in medical or surgical intervention to
prevent permanent impairment to body
structure or bodily function.
– Complications will be classified in to four
complication categories:
▪Access site complication (access site including distal
to the site): Hematoma/bleeding, arterial/venous
occlusion/thrombosis, severe vasospasm, intimal
injury/dissection, pseudoaneurysm, arteriovenous
fistula, vascular perforation or rupture, arterial
embolization distal to puncture site.
▪ Treatment site complication (treatment site
including distal to the site): Hematoma/
bleeding, arterial/venous occlusion/thrombosis,
severe vasospasm, intimal injury/dissection,
pseudoaneurysm, arteriovenous fistula, vascular
perforation or rupture, arterial embolization
distal to treatment site.
▪Organ-specific complication:
∘Neurological: TIA, minor and major stroke,
seizure;
∘ Cardiovascular: Hypotension or hypertension
requiring treatment, arrhythmia requiring
treatment, myocardial ischemia/infarction,
chronic heart failure;
∘ Respiratory: Profound hypoxia, pulmonary
edema, respiratory arrest, pulmonary embolism,
pneumothorax;
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pancreatitis, peritonitis, abscess, perforation of
hollow viscus.
▪ Systemic complication: Allergic/anaphylactic
reaction, renal failure, idiosyncratic reaction to
drug, fluid/electrolyte imbalance. Amputation rate. Divided in to minor (below the
ankle) and major (above the ankle). Major amputation
is sub-divided in to below-the-knee and above-the
-knee. Planned and unplanned amputations will be
reported separately. Planned amputations are defined
as amputations that were planned prior to the
revascularization procedure, that is, when the
revascularization procedure is performed to improve
the vascularization (and thereby healing potential) of
the planned amputation wound.
 Rate of device-specific problems, for example, stent
fracture, stent migration.
Baseline characteristics
 Risk factors and comorbidities:
– Age;
– Gender;
– Hypertension: Systolic blood pressure ≥140
mmHg and/or diastolic blood pressure ≥ 90
mmHg, or if the patient is on antihypertensieve
therapy for the indication of hypertension;
– Hyperlipidemia: LDL-cholesterol >4.4 mmol/L
(>170 mg/dL) or triglycerides >2.0 mmol/L (>177
mg/dL), or if the patient is taking lipid-lowering
medication for the indication of hyperlipidemia;
– Diabetes mellitus: HbA1c >7% or if the patient
consumes oral hypoglycemic agents or uses insulin;
– Smoking: Current smoking status (active/
previous/never), number of pack years, number
of years since last smoked;
– Ischemic heart disease: History of myocardial
infarction, angina pectoris, previous percutaneous
or surgical coronary revascularization, positive
exercise test, anti-anginal therapy;
– Congestive heart failure: Ejection fraction <40%;
– Renal insufficiency: e-GFR <60 mL/min/1.73 m2;
– Cerebrovascular disease: Known carotid artery
disease and history of minor or major stroke or
transient ischemic attack (TIA).
 Medication, pre-, peri- and post-procedural,
(including dose, frequency and duration of use):
– Anticoagulants (Acenocoumarol, Fenprocoumon,
unfractioned or low molecular weight heparins, and
so on);
– Antithrombotic agents (Acetyl salicylic acid,
Clopidrogel, Dipyridamol, and so on);– Statins or other lipid-lowering agents;
– Beta-blockers;
– Angiotensin converting enzyme inhibitors;
– Angiotensin-II receptor antagonists;
– Insulin and oral hypoglycaemic agents;
– Medications for the treatment of IC
(Pentoxifylline, Buflomedil).
 Baseline anatomic characteristics of the target lesion
in the common iliac artery, as determined by DSA
and pre-operative CT-angiography or MR-
angiography:
– Arterial inflow: Impaired inflow is defined as
presence of hemodynamically significant
obstruction in the aorta;
– Arterial outflow: Impaired outflow is defined
as presence of hemodynamically significant
obstruction in the external iliac artery,
common femoral artery or both superficial
and deep femoral arteries. Isolated
hemodynamically significant obstruction in
either the superficial or deep femoral artery
will not be considered impaired outflow;
– Reference vessel diameter, obtained from
averaging 5mm segments proximal and distal to
the lesion;
– Involvement of origin/ostium;
– Lesion length, documented in centimeters and
classified as follows:
▪ Focal: ≤1 cm;
▪ Short: >1 and <3 cm;
▪ Intermediate: ≥ 3 and < 5 cm;
▪ Long: ≥ 5 cm;
▪ In case of vessel occlusion with a stenosed
segment, both the length of the stenosed
segment and the length of the occluded
segment should be reported.
– Occlusion or stenosis
– In case of stenosis▪Minimal luminal diameter;
▪ Percent diameter stenosis;
▪ Systolic pressure gradient, measured as
described previously.
– Calcification: Semi-quantitative distinction
between no, moderate, and heavy calcification at
the site of the lesion.
– TASC-classification.
 Baseline anatomic characteristics of other
hemodynamically significant lesions at the aortoiliac
and femoropopliteal level:
– Arterial segment(s):▪ Infra-renal abdominal aorta;
▪ Internal iliac artery;
▪ External iliac artery;
▪ Common femoral artery;
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▪ Superficial femoral artery;
▪ Popliteal artery.
– Lesion length, documented in centimeters and
classified as follows:
▪ Focal: ≤1 cm;
▪ Short: >1 and <5 cm;
▪ Intermediate: ≥ 5 and < 15 cm;
▪ Long: ≥ 15 cm;
▪ In case of vessel occlusion with a stenosed
segment, both the length of the stenosed
segment and the length of the occluded
segment should be reported.
– Occlusion or stenosis
 Crural outflow: Each of the crural arteries with
patency directly to the foot will score 1 point. A
patent dorsal and plantar pedal arch will each score
1 point. This will lead to a score of 0 to 5, indicating
crural outflow. As it is not standard procedure to
make a DSA of the crural arteries during iliac
interventions, pre-operative CT-A or MR-A will be
used to score this.
 Presence of multilevel disease: Defined as presence
of significant obstructive lesions at more than one
level in the same limb (aortoiliac, femoropopliteal
and crural). When patients are included with both
limbs, one limb can have multilevel disease, while
the other limb does not.
 Disease-related health status and quality of life: As
defined by the Walking Impairment Questionnaire
(WIQ) and RAND-36 questionnaire.
 Rutherford stage.
 Functional status:
– In patients with IC: Claudication onset time
(COT) and absolute claudication time (ACT) on
a standardized treadmill test (3.2 km/h at a 12%
grade for a maximum of 5 minutes).
 Hemodynamic status:
– In patients with IC: ABI at rest and after
standardized treadmill test;
– In patients with CLI: Systolic ankle pressure and
ABI.
 Degree of stenosis and peak systolic velocity ratio on
DUS.
Procedure-related parameters
 Grams of intravenous iodine used for contrast. The
amount of millilitres used will be scored during the
procedure, and post-hoc the amount of iodine will
be calculated. In our centre, we use VisipaqueW,
which contains 320mg of Iodine per ml
 Radiation time and dosage, as is measured by the
fluoroscopy device Amount and type of materials used (guidewires,
sheaths, balloons, catheters)
 Type, diameter, number and length of stents used
 Lesion characteristics after treatment:
– Arterial inflow: Impaired inflow is defined as
presence of hemodynamically significant
obstruction in the aorta;
– Arterial outflow: Impaired outflow is defined as
presence of hemodynamically significant
obstruction in the external iliac artery, common
femoral artery or both superficial and deep
femoral arteries. Isolated hemodynamically
significant obstruction in either the superficial or
deep femoral artery will not be considered
impaired outflow;
– Minimal luminal diameter (MLD);
– Percent diameter stenosis;




Parameters scored during regular follow-up
 Disease-related health status and quality of life: As
defined by the Walking Impairment Questionnaire
(WIQ) and RAND-36 questionnaire.
 Rutherford stage.
 Functional status:– In patients with IC: Claudication onset time
(COT) and absolute claudication time (ACT) on
a standardized treadmill test (3.2 km/h at a 12%
grade for a maximum of 5 minutes).
 Hemodynamic status:
– In patients with IC: ABI at rest and after
standardized treadmill test;
– In patients with CLI: Systolic ankle pressure and
ABI.
 Degree of stenosis and peak systolic velocity ratio on
DUS.
 Occurrence of amputation.
 Mortality.
Parameters scored in case of restenosis or reocclusion
 Anatomic characteristics of the restenosis or
occlusion in the stent in the common iliac artery:
– Arterial inflow: Impaired inflow is defined as
presence of hemodynamically significant
obstruction in the aorta.
– Arterial outflow: Impaired outflow is defined as
presence of hemodynamically significant
obstruction in the external iliac artery, common
femoral artery or both superficial and deep femoral
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obstruction in either the superficial or deep femoral
artery will not be considered impaired outflow.
– Relation of stenosis or occlusion to the stent:
▪ Proximal edge, defined as 1 cm proximal and
distal to the proximal edge of the stent;
▪ In-stent, defined as 1 cm distal from the
proximal to 1 cm proximal from the distal end;
▪Distal edge, defined as 1 cm proximal and distal
to the distal edge of the stent.
– Lesion length, documented in centimeters and
classified as follows:
▪ Focal: ≤1 cm;
▪ Short: >1 and <3 cm;
▪ Intermediate: ≥ 3 and < 5 cm;
▪ Long: ≥ 5 cm;
▪ In case of vessel occlusion with a stenosed
segment, both the length of the stenosed
segment and the length of the occluded
segment should be reported.
– Occlusion or stenosis;
– In case of stenosis:▪Minimal luminal diameter;
▪ Percent diameter stenosis;
▪ Systolic pressure gradient. Procedural success rate of re-intervention.
Randomization, blinding and treatment allocation
All symptomatic patients in whom a hemodynamically
significant lesion of the CIA is suspected will be included.
This is assessed using DUS and either CT-angiography or
MR-angiography. A hemodynamically significant lesion is
suspected if DUS shows a peak systolic velocity ratio of
≥2.4 and/or CT-angiography or MR-angiography shows a
diameter reduction of ≥50%. Any suspected significant le-
sion is initially included, and informed consent obtained,
even if pre-operative imaging shows a stenosis with a length
of less than 3 cm. After the pre-intervention DSA and
intra-arterial systolic blood pressure gradient measurement
have been performed, the treating physician will make the
final decision if the patient meets the inclusion criteria. If
there is a stenosis with a length of more than 3 cm, or an
occlusion, the patient will be randomized. All patients
with stenoses with a length of less than 3 cm will be
excluded, but they will be registered, and informed con-
sent will have been obtained to store their data (Figure 2).
Randomization will be performed using an online registra-
tion and randomization program (Trans European Network
for Clinical Trial Services (TENALEA), http://tenalea.net).
Unstratified randomization will be used, with a minimization
algorithm based on occlusion vs stenosis, and endovascu-
lar vs hybrid procedures. If a patient has bilateral iliac
lesions that are eligible, the symptomatic limb will be
included. In case both limbs are symptomatic, the leg withthe lowest ABI will be included. Both legs will receive the
same treatment. The patient will be allocated to either the
Advanta V12 PTFE-covered stent, or to an uncovered
balloon-expandable stent. Patients will be blinded for the
treatment they receive. When patients are under local or
regional anesthesia, a sterile operating theatre napkin will
be placed in such a manner that the patient cannot see the
procedure and the stent in particular. The physician will
make sure not to mention the type of stent prior, during or
after the procedure. The physician performing the proced-
ure will not be blinded, as this is not possible practically.
The type of stent used will not be documented in the
patient’s medical record. Post-operative ABI’s, DUS and
scoring of Rutherford classification will be performed by
vascular technicians who are blinded for the type of stent
used. Therefore, this is a double-blind study.
In both centers, we have, as a standard procedure, a
separate file in which the product sticker of every placed
stent is put, coupled with the name, birth date and pa-
tient number of the patient that received the stent. Nei-
ther the patient, nor the personnel who perform post-
operative investigations, nor the analyst analyzing the
data have insight in to this file; therefore keeping this file
does not threaten the double-blind nature of this study.
The indication for breaking the randomization code is
the need for open surgical or endovascular re-intervention
if the treating physician feels this is required. The physician
will then contact the coordinating or one of the principal
investigators, who will reveal the type of stent and docu-
ment breaking of the randomization code. Alternatively,
this can be looked up in the separate file described in the
previous paragraph.
Study procedures
Digital Subtraction Angiography (DSA)
This is a widely used diagnostic technique to visualize
peripheral arteries using fluoroscopy. A pre-contrast
image is made, after which intra-arterial contrast is given
proximal to the area that needs to be visualized. Using
digital techniques, the pre-contrast image is subtracted
from later images, thereby visualizing the degree of con-
trast in the arterial lumen without interference from
bony or soft tissue structures.
Duplex Ultrasonography
This is a non-invasive diagnostic technique to estimate
stenoses or occlusions in peripheral arteries. It incorpo-
rates two elements:
 Grayscale: Uses ultrasound to directly visualize the
structure of the vessel. No motion or bloodflow is
assessed. In this way, stenosis or occlusion can be
directly visualized
Symptomatic atherosclerotic 
Common Iliac Artery lesion 
Informed Consent 
Pre-intervention DSA
Stenosis shorter than 3 cm 
Occlusion or stenosis longer
than 3 cm 
Randomization 
Bare-metal balloon-
expandable stent (N=87)  
Advanta V12 (N=87) 
Registration only 
Figure 2 Flowchart describing the inclusion and randomization of patients.
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in the vessel. This is expressed as peak-systolic
velocity (PSV), the highest velocity of the blood,
during the systolic phase, in cm/sec. In a stenosis,
the PSV will increase. When a stenosis is suspected,
the peak-systolic velocity ratio is calculated. This is
defined as the ratio of intra-stenotic PSV to pre-
stenotic PSV. A ratio of >2.4 will be defined as a
significant stenosis. When the vessel is occluded, no
flow will be measured.
All study-related DUS are required to be performed in
the vascular lab of the hospital by dedicated laboratory
personnel who are blinded for the type of stent used.
ABI measurement
Systolic pressure in both arms is measured, using an
automatic blood pressure monitor. The higher of the
two will be used. Next, a blood pressure cuff is placed
around the patient’s calf. Using a Doppler ultrasound de-
vice the dorsal pedal artery and posterior tibial artery are
located. The blood pressure cuff is inflated until the
Doppler signal disappears, and then slowly deflated. The
pressure at which a Doppler signal reappears is docu-
mented for both arteries. The higher of the two is then
divided by the systolic pressure in the arm. This is the ABI.
When a standardized treadmill test (in patients with IC) isperformed, this ABI measurement will be performed prior
to the test (ABI in rest) and after completion of the test
(ABI after exercise). All study-related ABI measurements
are required to be performed in the vascular lab of the hos-
pital by dedicated laboratory personnel who are blinded for
the type of stent used.
Standardized treadmill test
Patients are required to walk at 3.2 km/h at a 12% grade for
a maximum of 5 minutes on a treadmill. Claudication onset
time (COT) will be measured (in minutes and seconds),
which is defined as the time after initiation of exercise when
the patients first experiences symptoms of claudication, and
absolute claudication time (ACT), which is defined as the
time after initiation of exercise until the patient cannot con-
tinue due to severe claudication pain. Patients with CLI are
not required to undergo the standardized treadmill test. All
study-related treadmill tests are required to be performed
in the vascular lab of the hospital by dedicated laboratory
personnel who are blinded for the type of stent used.
Walking Impairment Questionnaire (WIQ)
The WIQ is a short, easy to fill out 14-item questionnaire
that evaluates the degree of walking impairment in patients
with intermittent claudication on three domains; walking
distance, walking speed and the ability to climb stairs.
These three domains represent common daily activities
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PAOD and contribute to the degree of walking impairment.
A Dutch translation, using the metric system, has been vali-
dated [57].
RAND-36 questionnaire
The RAND-36 questionnaire is a short, easy to fill out
36-item questionnaire, designed for scoring general
quality of life and health status [58]. It is identical to the
SF-36, but uses a slightly different scoring algorithm
[59]. A translated Dutch version has been made, which
has been validated [60]. It covers eight domains, and
assesses these domains over the past 4 weeks. Domains
can score from 0 to 100 points, with higher scores repre-
senting less physical limitation, fewer symptoms, greater
treatment satisfaction, or better quality of life. The
domains that are tested are: physical functioning, social
functioning, physical role impairment, emotional role
impairment, vitality, pain, mental health and general
health perception. A separate question assesses health
change with standardized response choices.
Follow up scheme
During follow-up, any change in baseline characteristics,
complication, or newly developed (re)stenosis or (re)oc-
clusion will have to be documented as described in ’End-
points/parameters’.
Pre-operative
Pre-operative, DUS will be performed to document the
occlusion or degree of the stenosis in the iliac and com-
mon femoral artery. This is mandatory, as this is the
modality that will be used during follow-up. Addition-
ally, either CT-angiography (CT-A) or MR-angiography
(MR-A) of the entire lower extremity must be performed
at the physician’s discretion. An ABI will be measured,
including a treadmill test in claudicants. These are all
part of our regular pre-operative work-up. In most cases,
one or more of these investigations will have been per-
formed prior to inclusion. When this has been no longer
than 3 months prior to inclusion, the investigation will
not have to be repeated for study purposes. All other
relevant study parameters will be documented and
patients will be asked to fill in the RAND-36 and WIQ.
Per-operative
Prior to placement of the stent, a DSA in two imaging
planes, with at least 30, but preferably more than 45
degrees difference in rotation will be performed, and a
systolic pressure gradient will be measured. After suc-
cessful stent placement, a DSA (in two imaging planes)
and systolic pressure gradient will once again be per-
formed. If open surgical and/or endovascular repair of
other arteries of the lower extremity was performed, thiswill be documented. Any complication that occurred
during the procedure will be documented.
1 month postoperative
At 1 month, patients will undergo an ABI with treadmill
test (patients with persistent CLI will only require ABI
measurement in rest). Any complication that occurred
within the first 30 days will be scored. Patients will be
asked to fill in the RAND-36 and the WIQ.
6, 12 and 24 months postoperative
At 6, 12 and 24 months, ABI and treadmill test will be
performed, as well as a DUS, and patients will be asked
to fill in the RAND-36 and WIQ. If DUS shows a sten-
osis, defined as a peak systolic velocity rate of ≥2.4, or is
inconclusive, CT-A, MR-A or DSA will be performed. If
an in-stent stenosis or occlusion is identified, this will be
documented and treated within 1 month. Table 3 sum-
marizes the study procedures at different moments.
Unplanned visits
Patients might present themselves at the outpatient
clinic or the emergency ward in between study visits,
with (recurrent) symptoms and complaints of PAOD. In
this case at least ABI in rest and DUS is mandatory. If
DUS shows a stenosis, defined as a peak systolic velocity
rate of ≥2.4, or is inconclusive, CT-A, MR-A or DSA will
be performed. If an in-stent stenosis or occlusion is
identified, this will be documented and treated within 1
month. Patients will then resume their regular follow-up
scheme as planned.
Withdrawal of individual subjects
Subjects can leave the study at any time for any reason if
they wish to do so without any consequences. The inves-
tigator can decide to withdraw a subject from the study
for urgent medical reasons. This will be recorded in the
CRF and the physician is required to notify the Principal
Investigator.
Replacement of individual subjects after withdrawal
Patients that have been randomized and are withdrawn
from the study will be not replaced. They will be consid-
ered lost to follow-up and included in the data analysis
based on intention-to-treat. Patients that have been
included but are withdrawn prior to randomization will
be replaced. This will be documented.
Follow-up of subjects withdrawn from treatment
Patients that for whatever reason receive a different
treatment than randomized, or received no treatment
will be followed-up and included in the trial, based on
intention-to-treat. Patients that are withdrawn from
follow-up will be considered lost to follow-up.
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If at any point during the study information becomes
available, either from interim analysis of results, or from
external sources, that the investigated device poses an
increased risk for participating patients, the study will be
terminated. Patients will be unblinded for the type of
stent they received. If applicable, they will receive add-
itional treatment or intervention.
Safety reporting
Section 10 WMO event
In accordance to section 10, subsection 1, of the WMO,
the investigator will inform the subjects and the review-
ing accredited medical ethical review committee
(METC) if anything occurs on the basis of which it
appears that the disadvantages of participation may be
significantly greater than was foreseen in the research
proposal. The study will be suspended pending further
review by the accredited METC, except insofar as sus-
pension would jeopardize the subjects’ health. The inves-
tigator will take care that all subjects are kept informed.
Adverse and serious adverse events
Adverse events are defined as any undesirable experi-
ence occurring to a subject during the clinical trial,
whether or not considered related to the investigational
treatment. All adverse events reported spontaneously by
the subject or observed by the investigator or his staff
will be recorded.
A serious adverse event is any untoward medical oc-
currence or effect that:
 Causes death, or is life threatening (at the time of
the event);
 Requires hospitalization or prolongation of existing
inpatients’ hospitalization;
 Results in persistent or significant disability or
incapacity.
All SAEs will be reported by the responsible investiga-
tor through the web portal ToetsingOnline to the accre-
dited METC that approved the protocol within 15 days
after the sponsor has first knowledge of the serious ad-
verse reactions.Table 3 Study procedures
Pre-ope-rative Per-ope-rative 1
DUS X
ABI (with or with-out treadmill test) X X
DSA X
WIQ/RAND-36 X X
DUS = Duplex ultrasonography, ABI = Ankle-brachial index, DSA = Digital subtractio
36-Item Health Survey.SAEs that result in death or are life threatening should
be reported expeditiously. The expedited reporting will
occur not later than 7 days after the responsible investi-
gator has first knowledge of the adverse reaction. This is
for a preliminary report, with another 8 days for comple-
tion of the report.
Follow-up of adverse events
All adverse events will be followed-up until they
have abated, or until a stable situation has been
reached. Depending on the event, follow up may re-
quire additional tests or medical procedures as indi-
cated, and/or referral to a general physician or a
medical specialist
Data safety monitoring board
Following the recommendations of the ’Quality as-
surance in human medical research’ charter (Dutch:
Kwaliteitsboring van mensgebonden onderzoek) by
the ‘Dutch Federation of Academic Medical Centers’
(Dutch: Nederlandse Federatie van Universitair Med-
ische Centra), we do not consider the formation of a
Data Safety Monitoring Board (DSMB) sensible. A
DSMB has several functions. First, is to assess
whether statistical significance can still likely be
reached or, on the other hand, may be reached pre-
liminarily for the main outcomes, and thus whether
the study group size should be changed. However,
our main outcomes are all scored at 2 years. So,
when a relevant group has reached the 2-year
follow-up, and an interim analysis would be sensible,
we will already have included all of our patients. So,
the interim analysis would not contribute anything
on that field.
A second function of the DSMB is to assess the
safety and (S)AE’s of the investigational products.
However, all stents that are used in the trial are regis-
tered for use in the iliac artery and have been used
for years. As well, virtually all complications are
procedure-related and not stent-related. Therefore, a
difference in safety or occurrence of (S)AE’s is un-
likely. Of course, the investigators and the METC will
monitor the occurrence and rate of (S)AE’s.month 6 months 12 months 24 months In case of restenosis
X X X X
X X X X
X
X X X
n angiography, WIQ = Walking Impairment Questionnaire, RAND-36 = RAND
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Statistical analysis will be performed for the complete
study population, as well as subgroup analysis for
patients with IC vs CLI, occlusions vs stenoses, and
endovascular vs hybrid procedures.
Descriptives
Descriptive analysis will be performed to compare the
baseline characteristics of both groups.
 Continuous data (age, BMI, length, and so on):
Averages with standard deviation (parametric data)
or medians with percentiles (non-parametric data)
will be calculated for both groups.
 Categorical data (TASC type, co-morbidities, and so
on): Frequencies will be calculated for both groups.
Distribution of Rutherford categories during baseline
and follow-up will be given as percentages per category.
No statistical analysis will be performed.
Comparative statistics
The primary and secondary endpoints as mentioned in
’Endpoints/parameters’ will be compared using statistical
methods.
Actuarial analysis
Absence of binary restenosis rate and reocclusion rate will
be calculated with actuarial (life-table) analysis and will be
expressed as a percentage with a standard error and 95%
CIs. Logrank tests will be used to determine if differences
between the estimates are significant. For these endpoints,
we will also calculate a combined endpoint with survival,
for example, binary restenosis-free survival etc. Based on
the literature, we expect that mortality will be negligible
and will not influence the results, and these separate ana-
lyses will be performed to check this assumption.
Univariate analysis
Univariate analysis will be performed to assess differ-
ences in the other aforementioned primary and second-
ary endpoints.
Continuous data: Averages with standard deviation
(parametric data) or medians with percentiles (non-
parametric data) will be calculated. Differences between
both groups will be tested using a Student’s t-test
(parametric data) or a Mann–Whitney U-test (non-
parametric data). Differences with a P-value <0.05 will
be considered statistically significant. The following
endpoints will be assessed:
 Post-intervention COT and ACT;
 Mean ABI.Categorical data: Frequencies will be calculated and
difference between both groups will be tested using
Chi-squared test. Differences with a P-value <0.05 will
be considered statistically significant. The following
secondary endpoints will be assessed: Target lesion revascularization rate and target
extremity revascularization rate;
 Procedural, technical and device success rate;
 Mortality rate, complication rate, amputation rate;
 Rate of device-specific problems.
Interim analysis
Interim analysis is not deemed sensible, as described
earlier.
Software
All statistical analysis will be performed with the Statistical
Package for the Social Sciences (SPSS) version 16.0 or up
(IBM, Armonk, NY, USA).
Ethical considerations
Regulation statement
This study will be conducted according to the principles of
the Declaration of Helsinki (version: October 2008) and in
accordance with the Medical Research Involving Human
Subjects Act (Dutch: Wet Medisch-wetenschappelijk
Onderzoek met mensen; WMO).
Recruitment and consent
All patients who present at the outpatient clinic or
emergency ward with symptomatic PAOD of the
common iliac artery will be considered possibly eli-
gible for inclusion. The present surgical or radio-
logical resident or staff member will screen the
patient for meeting the in- and exclusion criteria. If
for whatever reason the physician at this moment
does not screen the patient, any other involved phys-
ician or one of the investigators may include the pa-
tient at a later moment. When the patient meets the
inclusion criteria, the physician will then inform the
patient of the study, including the risks and burdens
as mentioned before and the availability of an inde-
pendent physician. A written information letter will
be presented to the patient to read, this will include
contact details of an independent physician. The pa-
tient will then be offered the opportunity to ask ques-
tions. Patients will be offered 24 hours to consider
their decision. When they agree to participate in the
study, they will be asked to fill out an informed con-
sent form. Both the information letter and the informed
consent form are attached as separate documents to this
protocol.
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Participating patients will need to make five study-
related hospital visits. One CT-angiography or MR-
angiography, four DUS and five ABI measurements
with treadmill tests (only in patients with IC) will be
performed. When compared to our standard work-up
and follow-up, patients need to make two extra hos-
pital visits, and will receive two extra DUS and three
extra ABI measurements with treadmill test. When
DUS shows possible restenosis, patients will receive
additional DSA, CT-angiography or MR-angiography.
This is standard procedure for all patients. Patients
will also be asked to fill in two questionnaires five
times. Patients who participate may benefit by being
treated with a stent that may have a lower restenosis
rate.Compensation for injury
The investigator has an insurance which is in accord-
ance with the legal requirements in the Netherlands
(Article 7 WMO and the Measure regarding Compul-
sory Insurance for Clinical Research in Humans of 23
June 2003). This insurance provides cover for damage
to research subjects through injury or death caused
by the study.




The Netherlands (+31) 030–241133
The maximum coverage of this insurance is:
1. € 450.000,- (that is, four hundred and fifty thousand
Euro) for death or injury for each subject who
participates in the Research;
2. € 3.500.000,- (that is, three million five hundred
thousand Euro) for death or injury for all subjects
who participate in the Research;
3. € 5.000.000,- (that is, five million Euro) for the total
damage incurred by the organization for all damage
disclosed by scientific research for the Sponsor as
‘verrichter’ in the meaning of said Act in each year of
insurance coverage.
The insurance applies to the damage that becomes ap-
parent during the study or within 4 years after the end
of the study.
Incentives
Participating patients will not receive any incentives or
compensation.Administrative aspects and publication
Handling and storage of data and documents
Data will be documented using an online interface and
will be stored on a separate server. This database and
server was created for the DEALL (Dutch Endovascular
ALLiance) research group, and use of this database and
server was previously approved by the board of the
Maasstad Hospital Rotterdam and Sint Antonius Hos-
pital Nieuwegein for collection and storage of observa-
tional data. Only the coordinating and principal
investigators per site will have access to the source data.
All data will be handled anonymously. Each participant
will receive a study number, consisting of the letters DIS
followed by three numbers. These numbers will be
awarded increasingly, according to time of inclusion. So,
the first participant will receive DIS-001, and so on. This
number will be used in data analysis or any publications
or reports on the trial. Only the coordinating investiga-
tor and principal investigators will have access to the key
file which contains the coupling of the study number
with patients personal data.
The handling of personal data complies with the
Dutch Personal Data Protection Act (in Dutch: De Wet
Bescherming Persoonsgegevens, Wbp).
Amendments
Amendments are changes made to the research after a
favorable opinion by the accredited METC has been
given. All amendments will be notified to the METC
that gave a favorable opinion.
Annual progress report
The sponsor/investigator will submit a summary of the
progress of the trial to the accredited METC once a year.
Information will be provided on the date of inclusion of
the first subject, numbers of subjects included and num-
bers of subjects that have completed the trial, serious ad-
verse events/serious adverse reactions, other problems,
and amendments.
End of study report
The investigator will notify the accredited METC of the
end of the study within a period of 8 weeks. The end of
the study is defined as the last patient’s last visit.
In case the study is ended prematurely, the investiga-
tor will notify the accredited METC, including the rea-
sons for the premature termination.
Within one year after the end of the study, the investi-
gator/sponsor will submit a final study report with the
results of the study, including any publications/abstracts
of the study, to the accredited METC.
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After acceptance of the study protocol, the study proto-
col will be submitted to a peer-reviewed journal that
publishes study protocols. The first journal that it will be
submitted to is the open access, peer-reviewed, online
journal Trials. The trial will also be registered in the
Dutch Trial Register (NTR, in Dutch: Nederlands Trial
Register),
After completion of the trial, results, regardless of the
outcome, will be submitted for publication in a peer-
reviewed journal.
Trial status
Inclusion of patients will commence 1 May 2012.
Definitions
ABI, Ankle-brachial index. Defined as the ratio between
the highest systolic pressure in both brachial arteries and
the highest systolic pressure in the crural arteries. In
patients without CLI this is repeated after the standar-
dized treadmill test, termed ‘ABI in rest’ and ‘ABI after ex-
ercise’; ABR form, General Assessment and Registration
form, is the application required for submission to the
accredited Ethics Committee (in Dutch: Algemene Beoor-
deling en Registratie); Absence of binary restenosis, Ab-
sence of hemodynamically significant obstruction (see
definition) after endovascular intervention; ACT, Absolute
claudication time. Defined as the time (in minutes and
seconds) after initiation of the treadmill test when the pa-
tient cannot walk any further due to severe the patient
cannot walk any further due to severe claudication pain;
Aortoiliac level, Proximal limit: Origin of the renal arter-
ies. Distal limit: Deep circumflex iliac artery inguinal liga-
ment; COT, Claudication onset time. Defined as the time
(in minutes and seconds) after initiation of the treadmill
test when patient first experiences symptoms of claudica-
tion; Crural level, Proximal limit: Origin of anterior tibial
artery.Including foot arteries; DSA, Digital subtraction
angiography. Before and after every intervention a DSA of
the aortoiliac level will be performed and saved. DSA will
be performed in two imaging planes with at least 30 but
preferably more than 45 degrees difference in rotation.
DSA will be performed according to a standard protocol;
Femoro-popliteal level, Proximal limit: Deep circumflex
iliac artery inguinal ligament. Distal limit: Origin of anter-
ior tibial artery; Hemodynamically significant obstruction,
Hemodynamic significance can be assessed using the fol-
lowing measurement techniques (in hierarchical order):
Intra-arterial translesional systolic blood pressure gra-
dient >10 mmHg as assessed by using a 70cm straight
catheter (4F) without side holes which is withdrawn
through the stenosis. Intravascular ultrasound (IVUS)
measurements indicating ≥50% diameter stenosis.
Intra-arterial DSA,indicating ≥50% diameter stenosis.CT-angiography or MR-angiography indicating ≥50%
diameter stenosis. DUS indicating ≥50% diameter
stenosis as defined by a peak systolic velocity ratio
>2.4 (Defined as the ratio of intra-stenotic peak sys-
tolic velocity to pre-stenotic peak systolic velocity);
MLD, Minimal luminal diameter. The minimal lu-
minal diameter in a stenosis as measured by DSA;
Standardized treadmill test, Patients are required to
walk with 3.2 km/h at a 12% grade for a maximum
of 5 minutes on a treadmill. Claudication onset time
(COT) and absolute claudication time (ACT) are
determined in minutes and seconds.
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